Search Results - "van der Meer, FJM"

Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study by Heijdra, Jessica M, Al Arashi, Wala, de Jager, Nico C B, Cloesmeijer, Michael E, Bukkems, Laura H, Zwaan, Christian M, Leebeek, Frank W G, Mathôt, Ron A A, Cnossen, Marjon H, Cnossen, MH, Leebeek, FWG, Fijnvandraat, K, Mathôt, RAA, Meijer, K, Kruip, MJHA, Polinder, S, Coppens, M, Tamminga, RYJ, Laros-van Gorkom, BAP, Brons, P, Schols, SEM, van der Meer, FJM, Eikenboom, HCJ, Schutgens, REG, Fischer, K, Heubel-Moenen, F, Nieuwenhuizen, L, Ypma, P, Driessens, MHE, Zwaan, CM, van Vliet, I, Collins, PW, Liesner, R, Chowdary, P, Keeling, D, Lock, J, Hazendonk, HCAM, van Moort, I, Preijers, T, Heijdra, JM, de Jager, NCB, Goedhart, MCHJ, Bukkems, LH, Al Arashi, W, Cloesmeijer, ME, Janssen, A

“…IntroductionVon Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures…”
Get full text

Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study by BLOM, J. W., VANDERSCHOOT, J. P. M., OOSTINDIËR, M. J., OSANTO, S., VAN DER MEER, F. J. M., ROSENDAAL, F. R.

“…Background: The incidence of venous thrombosis (VT) for cancer patients is increased compared with patients without cancer, but estimations of the incidence…”
Get full text

Current perspective of venous thrombosis in the upper extremity by FLINTERMAN, L. E., VAN DER MEER, F. J. M., ROSENDAAL, F. R., DOGGEN, C. J. M.

“…Venous thrombosis of the upper extremity is a rare disease. Therefore, not as much is known about risk factors, treatment and the risk of recurrence as for…”
Get full text

Infectious Complications of Central Venous Catheters Increase the Risk of Catheter-Related Thrombosis in Hematology Patients: A Prospective Study by VAN ROODEN, Cornelis J, SCHIPPERS, Emile F, BARGE, Renée M. Y, ROSENDAAL, Frits R, GUIOT, Henri F. L, VAN DER MEER, Felix J. M, EDO MEINDERS, A, HUISMAN, Menno V

“…We studied whether the risk of central venous catheter (CVC) -related thrombosis increased after an episode of CVC-related infection in patients undergoing…”
Get full text

Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT) by VOSSEN, C. Y., CONARD, J., FONTCUBERTA, J., MAKRIS, M., VAN DER MEER, F. J. M., PABINGER, I., PALARETI, G., PRESTON, F. E., SCHARRER, I., SOUTO, J. C., SVENSSON, P., WALKER, I. D., ROSENDAAL, F. R.

“…Background: Reliable risk estimates for venous thrombosis in families with inherited thrombophilia are scarce but necessary for determining optimal screening…”
Get full text

Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts by den Exter, Paul L., Kroft, Lucia J.M., Gonsalves, Carol, Le Gal, Gregoire, Schaefer‐Prokop, Cornelia M., Carrier, Marc, Huisman, Menno V., Klok, Frederikus A.

“…Improved imaging techniques have increased the incidence of subsegmental pulmonary embolism (ssPE). Indirect evidence is suggesting that ssPE may represent a…”
Get full text

Daily vitamin K supplementation improves anticoagulant stability by ROMBOUTS, E. K., ROSENDAAL, F. R., VAN DER MEER, F. J. M.

“…Background: One of the causes of unstable anticoagulant control in patients using vitamin K antagonists is a fluctuating intake of vitamin K. Research suggests…”
Get full text

Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia by Vossen, Carla Y, Walker, Isobel D, Svensson, Peter, Souto, Juan C, Scharrer, Inge, Preston, F Eric, Palareti, Gualtiero, Pabinger, Ingrid, van der Meer, Felix J.M, Makris, Mike, Fontcuberta, Jordi, Conard, Jacqueline, Rosendaal, Frits R

“…OBJECTIVE—Few comprehensive data are available on the recurrence rate of venous thrombosis in carriers of thrombophilic defects from thrombophilic families. We…”
Get full text

Long‐term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users by VERHOEF, T. I., REDEKOP, W. K., BUIKEMA, M. M., SCHALEKAMP, T., VAN DER MEER, F. J. M., LE CESSIE, S, WESSELS, J. A. M., VAN SCHIE, R. M. F., DE BOER, A., TEICHERT, M., VISSER, L. E., MAITLAND‐VAN DER ZEE, A. H.

“…Background:  The required acenocoumarol dose and the risk of underanticoagulation and overanticoagulation are associated with the CYP2C9 and VKORC1 genotypes…”
Get full text

Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study by Janssen, Harry L.A., Meinardi, Johan R., Vleggaar, Frank P., van Uum, Stan H.M., Haagsma, Elizabeth B., van der Meer, Felix J.M., van Hattum, Jan, Chamuleau, Robert A. F.M., Adang, Rob P., Vandenbroucke, Jan P., van Hoek, Bart, Rosendaal, Frits R.

“…In a collaborative multicenter case-control study, we investigated the effect of factor V Leiden mutation, prothrombin gene mutation, and inherited…”
Get full text

Increased fetal loss in women with heritable thrombophilia by Preston, F E, Rosendaal, F R, Walker, I D, Briët, E, Berntorp, E, Conard, J, Fontcuberta, J, Makris, M, Mariani, G, Noteboom, W, Pabinger, I, Legnani, C, Scharrer, I, Schulman, S, van der Meer, F J

“…A successful outcome of pregnancy requires an efficient uteroplacental vascular system. Since this system may be compromised by disorders of haemostasis…”
Get more information

Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves by Cannegieter, S.C, Rosendaal, F.R, Wintzen, A.R, van der Meer, F.J.M, Vandenbroucke, J.P, Briet, E

“…Patients with mechanical heart-valve prostheses receive lifelong, high-intensity oral anticoagulant therapy to prevent thromboembolic complications, but this…”
Get full text

Familial thrombophilia and lifetime risk of venous thrombosis by Vossen, C. Y., Conard, J., Fontcuberta, J., Makris, M., Van Der Meer, F. J. M., Pabinger, I., Palareti, G., Preston, F. E., Scharrer, I., Souto, J. C., Svensson, P., Walker, I. D., Rosendaal, F. R.

“…Summary  Background : We started a large multicenter prospective follow‐up study to provide reliable risk estimates of venous thrombosis in families with…”
Get full text

Patient self‐management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life by Gadisseur, A. P. A., Kaptein, A. A., Breukink‐Engbers, W. G. M., Van Der Meer, F. J. M., R. Rosendaal, F.

“…Background: Oral anticoagulant therapy (OAT) implies frequent blood checks and dose changes to prevent thromboembolic or hemorrhagic complications. This may…”
Get full text

An evaluation of gene–gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol by VAN SCHIE, R. M. F., BABAJEFF, A. M. V., SCHALEKAMP, T., WESSELS, J. A. M., LE CESSIE, S., de BOER, A., VAN DER MEER, F. J. M., VAN MEEGEN, E., VERHOEF, T. I., ROSENDAAL, F. R., MAITLAND‐VAN DER ZEE, A. H.

“…Background:  Previous studies have provided contradictory results regarding the interaction between the CYP2C9 and VKORC1 genotypes affecting various outcome…”
Get full text

The use of rituximab therapy in patients with acquired factor v inhibitors by Navarrete, M.A., van der Meer, F.J.M., Damiani, G., Diaz, A., Eikenboom, J.

Get full text

The Leiden Thrombophilia Study (LETS) by van der Meer, F J, Koster, T, Vandenbroucke, J P, Briët, E, Rosendaal, F R

Get more information

Hereditary thrombophilia and fetal loss: a prospective follow‐up study by Vossen, C. Y., Preston, F. E., Conard, J., Fontcuberta, J., Makris, M., Van Der Meer, F. J. M., Pabinger, I., Palareti, G., Scharrer, I., Souto, J. C., Svensson, P., Walker, I. D., Rosendaal, F. R.

“…Background: As the placental vessels are dependent on the normal balance of procoagulant and anticoagulant mechanisms, inherited thrombophilia may be…”
Get full text

Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler‐ultrasound by Van Rooden, Cornelis J., Rosendaal, Frits R., Barge, Renée M. Y., Van Oostayen, Jacques A., Van Der Meer, Felix J.M., Meinders, A. Edo, Huisman, Menno V.

“…Patients with a central venous catheter (CVC) who receive intensive chemotherapy or a stem cell transplantation for haematological disease are at risk for…”
Get full text

Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon by Fihn, Stephan D, Gadisseur, Alain A P, Pasterkamp, Edwin, van der Meer, Felix J M, Breukink-Engbers, W G Mimi, Geven-Boere, Lya M, van Meegen, Erik, de Vries-Goldschmeding, Hanneke, Antheunissen-Anneveld, Irma, van't Hoff, Annelies R, Harderman, Derk, Smink, Margriet, Rosendaal, Frits R

“…Variability in the control of oral anticoagulant therapy has been associated with a heightened risk of complications. We compared control of anticoagulation…”
Get more information